Protective effects of BAY 41-2272 (sGC stimulator) on hypertension, heart, and cardiomyocyte hypertrophy induced by chronic L-NAME treatment in rats

scientific article published on 01 March 2006

Protective effects of BAY 41-2272 (sGC stimulator) on hypertension, heart, and cardiomyocyte hypertrophy induced by chronic L-NAME treatment in rats is …
instance of (P31):
scholarly articleQ13442814

External links are
P698PubMed publication ID16633081

P50authorEdson AntunesQ56686201
Gilberto de NucciQ5561420
P2093author name stringRenato Faro
Ana Maria Aparecida Guaraldo
Marcos Zanfolin
Eugênio G Araujo
P433issue3
P304page(s)391-395
P577publication date2006-03-01
P1433published inJournal of Cardiovascular PharmacologyQ2125808
P1476titleProtective effects of BAY 41-2272 (sGC stimulator) on hypertension, heart, and cardiomyocyte hypertrophy induced by chronic L-NAME treatment in rats
P478volume47

Reverse relations

cites work (P2860)
Q37193830Antigrowth properties of BAY 41-2272 in vascular smooth muscle cells
Q45664565BAY 41-2272 Treatment Improves Acetylcholine-Induced Aortic Relaxation in L-NAME Hypertensive Rats.
Q35204828Cardiac NO signalling in the metabolic syndrome
Q37420916Cyclic GMP signaling in cardiovascular pathophysiology and therapeutics
Q35619526Effect of nitric oxide synthase inhibition on intrarenal oxygenation as evaluated by blood oxygenation level-dependent magnetic resonance imaging
Q28482185Effects of stimulation of soluble guanylate cyclase on diabetic nephropathy in diabetic eNOS knockout mice on top of angiotensin II receptor blockade
Q27692662Heme-dependent and independent soluble guanylate cyclase activators and vasodilation.
Q24656131NO-independent stimulators and activators of soluble guanylate cyclase: discovery and therapeutic potential
Q35375986NOX1, 2, 4, 5: counting out oxidative stress
Q38594785New medical therapies for heart failure
Q37766747Novel therapeutic targets for hypertension
Q36532454Pathophysiology of hypertension in the absence of nitric oxide/cyclic GMP signaling
Q58766337Role of Nitric Oxide in the Cardiovascular and Renal Systems
Q35010064Soluble guanylate cyclase as an emerging therapeutic target in cardiopulmonary disease
Q38093420Stimulators of soluble guanylyl cyclase: future clinical indications
Q36380981The soluble guanylyl cyclase activator bay 58-2667 selectively limits cardiomyocyte hypertrophy

Search more.